Pfizer and BioNTech Reiterate COVID-19 Vaccine Safety and Efficacy Data
Pfizer and BioNTech issued a statement on September 19, 2025, reaffirming the safety and efficacy of their COVID-19 vaccine. The companies reported over 5 billion doses distributed globally.
NEW YORK and MAINZ, Germany – On September 19, 2025, pharmaceutical companies Pfizer and BioNTech reaffirmed the safety and efficacy profile of their COVID-19 vaccine program, which has been ongoing for five years.
The companies reported that over 5 billion doses of the COVID-19 vaccine have been distributed globally. They cited randomized clinical trials, real-world effectiveness studies, and global pharmacovigilance data confirming the vaccine's role in preventing COVID-19 related hospitalizations, severe illness, and death.
According to the statement, more than 600 peer-reviewed publications and ongoing safety surveillance support these findings. Pfizer and BioNTech emphasized their commitment to scientific transparency, accountability, and public health.
The companies stated they will continue their collaboration to ensure the development and availability of vaccines worldwide.